Pemetrexed disodium
Based on 40 publication(s) in Google Scholar
Pemetrexed disodium (LY231514 disodium) is an antifolate, the Kis of the pentaglutamate of Pemetrexed disodium are 1.3, 7.2, and 65 nM for inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), respectively.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.79%
- CAS No.: 150399-23-8
- Formule: C20H19N5Na2O6
- Masse moléculaire:471.37
-
Stockage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Autophagy Compound Library
HY-L029
-
Peptidomimetic Library
HY-L033
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Anti-COVID-19 Compound Library
HY-L052
-
NMPA-Approved Drug Library
HY-L053
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Drug-Induced Liver Injury (DILI) Compound Library
HY-L076
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Chemotherapy Drug Library
HY-L112
-
EMA-Approved Drug Library
HY-L116
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Off-patent Drug Library
HY-L141
-
Cell Death Library
HY-L162
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
RNA Binding Bioactive Compound Library
HY-L248
Publications Citing Use of MedChemExpress (MCE) Pemetrexed disodium
More- Mol Cancer. 2024 Jan 10;23(1):12. [Abstract]
- Mol Cell. 2019 Dec 5;76(5):838-851.e5. [Abstract]
- Adv Sci (Weinh). 2026 Feb 3:e16660. [Abstract]
- J Clin Invest. 2021 Aug 2;131(15):e138022. [Abstract]
- Theranostics. 2020 May 15;10(13):6048-6060. [Abstract]
- J Exp Clin Cancer Res. 2025 Oct 21;44(1):293. [Abstract]
- J Control Release. 2023 Jan:353:490-506. [Abstract]
- Cell Rep Med. 2023 Feb 21;4(2):100911. [Abstract]
- Pharmacol Res. 2024 May 9:204:107208. [Abstract]
- J Pharm Anal. 2024 Aug;14(8):100984. [Abstract]
- Dev Cell. 2025 Sep 3:S1534-5807(25)00530-1. [Abstract]
- Acta Pharmacol Sin. 2021 Jan;42(1):108-114. [Abstract]
- ACS Appl Mater Interfaces. 2025 Oct 8;17(40):55861-55875. [Abstract]
- Cell Death Discov. 2022 Jul 5;8(1):307. [Abstract]
- Br J Cancer. 2023 Aug;129(3):531-540. [Abstract]
- Int J Pharm X. 2026 May 5:11:100558. [Abstract]
- Commun Biol. 2022 Jun 23;5(1):619. [Abstract]
- Eur J Pharmacol. 2025 Apr 2:996:177584. [Abstract]
- Int Immunopharmacol. 2023 Nov 3;125(Pt A):111158. [Abstract]
- Cell Rep Methods. 2023 Oct 23;3(10):100599. [Abstract]
- J Mol Med (Berl). 2019 Aug;97(8):1183-1193. [Abstract]
- Adv Ther. 2024 Jul 18.
- Sci Rep. 2025 Oct 16;15(1):36227. [Abstract]
- Bioengineering (Basel). 2025 Oct 19;12(10):1121. [Abstract]
- Heliyon. 2024 Nov 8;10(22):e40299. [Abstract]
- Eur J Med Res. 2025 Aug 4;30(1):704. [Abstract]
- Hum Cell. 2025 Apr 19;38(3):92. [Abstract]
- Integr Cancer Ther. 2024 Jan-Dec:23:15347354241273962. [Abstract]
- Clin Transl Oncol. 2022 Nov;24(11):2231-2240. [Abstract]
- Odontology. 2020 Apr;108(2):300-311. [Abstract]
- Pharmacol Res Perspect. 2020 Apr;8(2):e00575. [Abstract]
- Beilstein J Org Chem. 2017 Oct 25:13:2252-2263. [Abstract]
- Biol Methods Protoc. 2025 Feb 13;10(1):bpaf012. [Abstract]
- Res Sq. 2025 Sep 7.
- bioRxiv. 2025 August 15.
- bioRxiv. 2025 January 22.
- bioRxiv. 2025 January 21.
- bioRxiv. 2024 June 12.
- Research Square Print. September 27th, 2022.
- University of Texas. 2015.
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
Apoptosis Analysis
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
-
WB
Activité biologique
Ki: 1.3 nM (TS), 7.2 nM (DHFR), 65 nM (GARFT)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
3.29 μM
Compound: 3; PTX
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay
|
[PMID: 30927565] |
| GES1 | CC50 |
22.62 μM
Compound: 3; PTX
|
Cytotoxicity against human GES-1 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Cytotoxicity against human GES-1 cells assessed as reduction in cell viability after 24 hrs by MTT assay
|
[PMID: 30927565] |
| HepG2 | IC50 |
3.73 μM
Compound: 3; PTX
|
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay
|
[PMID: 30927565] |
| L02 | CC50 |
30.69 μM
Compound: 3; PTX
|
Cytotoxicity against human L02 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Cytotoxicity against human L02 cells assessed as reduction in cell viability after 24 hrs by MTT assay
|
[PMID: 30927565] |
| OVCAR-3 | IC50 |
4.35 μM
Compound: 3; PTX
|
Antiproliferative activity against human OVCAR3 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human OVCAR3 cells assessed as reduction in cell viability after 24 hrs by MTT assay
|
[PMID: 30927565] |
| SGC-7901 | IC50 |
6.96 μM
Compound: 3; PTX
|
Antiproliferative activity against human SGC7901 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human SGC7901 cells assessed as reduction in cell viability after 24 hrs by MTT assay
|
[PMID: 30927565] |
Pemetrexed (LY231514) disodium is a novel classical antifolate, the antitumor activity of which may result from simultaneous and multipie inhibition of several key folate-requiring enzymes via its polyglutamated metabolites. Pemetrexed (LY231514) is one of the best substrates that is known for the enzyme FPGS (Km=1.6 μM and Vmax/Km=621). It is likely that polyglutamation and the polyglutamated metabolites of LY231514 play profound roles in determining both the selectivity and the antitumor activity of this novel agent. Whereas LY23l5l4 only moderately inhibits TS (Ki=340 nM, recombinant mouse), the pentaglutamate of LY23l5l4 is 100-fold more potent (Ki=3.4 nM), making LY231514 one of the most potent folate-based TS inhibitors[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 150399-23-8
-
Appearance Solid
-
Masse moléculaire 471.37
-
Formule C20H19N5Na2O6
-
Color White to off-white
-
SMILES
O=C1NC(N)=NC2=C1C(CCC3=CC=C(C=C3)C(N[C@@H](CCC(O[Na])=O)C(O[Na])=O)=O)=CN2
-
Synonyms
LY231514 disodium
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (40)
-
Journal Impact Factor
-
Most Recent
-
Mol Cancer
Organoids derived from patients provide a new opportunity for research and individualized treatment of malignant peritoneal mesothelioma. [Abstract]2024 Jan 10;23(1):12. PMID: 38200517 -
Mol Cell
2019 Dec 5;76(5):838-851.e5. PMID: 31564558
Pemetrexed disodium purchased from MedChemExpress. Usage Cited in: Mol Cell. 2019 Dec 5;76(5):838-851.e5. [Abstract]
The relationship between SerG6m3 and Pemetrexed disodium (0.01-1.0 μM; 3 d) IC50.
-
Adv Sci (Weinh)
2026 Feb 3:e16660. PMID: 41632021 -
J Clin Invest
Serine hydroxymethyltransferase 2 expression promotes tumorigenesis in rhabdomyosarcoma with 12q13-q14 amplification. [Abstract]2021 Aug 2;131(15):e138022. PMID: 34166228 -
Theranostics
The deubiquitinating enzyme UCHL1 promotes resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase. [Abstract]2020 May 15;10(13):6048-6060. PMID: 32483437
Pemetrexed disodium purchased from MedChemExpress. Usage Cited in: Theranostics. 2020 May 15;10(13):6048-6060. [Abstract]
Western blot analysis of UCHL1 levels in PEM-R cells and their parental cells. The mRNA and protein levels of UCHL1 in the PEM-R cells are significantly increased, relative to in the parental cells.
Pemetrexed disodium purchased from MedChemExpress. Usage Cited in: Theranostics. 2020 May 15;10(13):6048-6060. [Abstract]
Immunofluorescence assay showing the expression and intracellular location of UCHL1 in NSCLC cells. Increased UCHL1 levels are observed in both the cytoplasm and the nucleus of the PEM-R cells.
-
J Exp Clin Cancer Res
FL496, an FL118-derived small molecule, induces growth inhibition, senescence, and apoptosis of malignant pleural mesothelioma (MPM) cells, and exhibits anti-MPM tumor efficacy strikingly superior to the pemetrexed-cisplatin combination. [Abstract]2025 Oct 21;44(1):293. PMID: 41121175 -
J Control Release
Effective combination of liposome-targeted chemotherapy and PD-L1 blockade of murine colon cancer. [Abstract]2023 Jan:353:490-506. PMID: 36460179
Pemetrexed disodium purchased from MedChemExpress. Usage Cited in: J Control Release. 2023 Jan:353:490-506. [Abstract]
Cell viability of MC38 and CT26 cells after incubation with DTX, PMX, DTX+PMX, DTX-LPs,PMX-LPs, and DTX/PMX-LPs for 48 and 72 hours (n = 4, equivalent PMX (Pemetrexed) concentration is 0.048, 0.16, 1.2, 6, 30 µg/ml).
Pemetrexed disodium purchased from MedChemExpress. Usage Cited in: J Control Release. 2023 Jan:353:490-506. [Abstract]
The apoptotic rate after treatment with different Pemetrexed (1.37 μg/mL; 24 h) of drugs and formulations
-
Cell Rep Med
Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study. [Abstract]2023 Feb 21;4(2):100911. PMID: 36657446 -
Pharmacol Res
2024 May 9:204:107208. PMID: 38729587 -
J Pharm Anal
Increasing the tumour targeting of antitumour drugs through anlotinib-mediated modulation of the extracellular matrix and the RhoA/ROCK signalling pathway. [Abstract]2024 Aug;14(8):100984. PMID: 39258171 -
Dev Cell
A pathological role of O-GlcNAcylation-driven TR11B production and function in lung adenocarcinoma. [Abstract]2025 Sep 3:S1534-5807(25)00530-1. PMID: 40930100 -
Acta Pharmacol Sin
Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway. [Abstract]2021 Jan;42(1):108-114. PMID: 32398685 -
ACS Appl Mater Interfaces
Feedback-Amplified Drug Delivery of αPD-L1-Modified Lipoplatin for Chronological Synergy in NSCLC through PD-L1 Upregulation. [Abstract]2025 Oct 8;17(40):55861-55875. PMID: 40997865 -
Cell Death Discov
Targeting mitochondrial one-carbon enzyme MTHFD2 together with pemetrexed confers therapeutic advantages in lung adenocarcinoma. [Abstract]2022 Jul 5;8(1):307. PMID: 35790743
Pemetrexed disodium purchased from MedChemExpress. Usage Cited in: Cell Death Discov. 2022 Jul 5;8(1):307. [Abstract]
The IC50 value of pemetrexed ( 0.039 to 50 μM, 5 days) in A549 cells.
Pemetrexed disodium purchased from MedChemExpress. Usage Cited in: Cell Death Discov. 2022 Jul 5;8(1):307. [Abstract]
A549 and H1299 cells were treated with pemetrexed (5 μM), DS18561882 (10 μM), or combination for 5 days. Cell proliferative abilities were detected by MTT assay.
-
Br J Cancer
2023 Aug;129(3):531-540. PMID: 37369845 -
Int J Pharm X
Bio-inspired self-assembly of omega-3 fatty acids and peptides for responsive drug delivery. [Abstract]2026 May 5:11:100558. PMID: 42205116 -
Commun Biol
Serine hydroxymethyltransferase as a potential target of antibacterial agents acting synergistically with one-carbon metabolism-related inhibitors. [Abstract]2022 Jun 23;5(1):619. PMID: 35739195 -
Eur J Pharmacol
GART promotes multiple myeloma malignancy via tumor stemness mediated by activating the HSP90α/CDK6/β-catenin axis. [Abstract]2025 Apr 2:996:177584. PMID: 40185325 -
Int Immunopharmacol
Pemetrexed ameliorates Con A-induced hepatic injury by restricting M1 macrophage activation. [Abstract]2023 Nov 3;125(Pt A):111158. PMID: 37925950 -
Cell Rep Methods
RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]2023 Oct 23;3(10):100599. PMID: 37797618 -
J Mol Med (Berl)
2019 Aug;97(8):1183-1193. PMID: 31201471 -
-
Sci Rep
2025 Oct 16;15(1):36227. PMID: 41102354 -
Bioengineering (Basel)
Precision Oncology for High-Grade Gliomas: A Tumor Organoid Model for Adjuvant Treatment Selection. [Abstract]2025 Oct 19;12(10):1121. PMID: 41155119 -
Heliyon
Synergistic effects of MK-1775 and gemcitabine on cytotoxicity in non-small cell lung cancer. [Abstract]2024 Nov 8;10(22):e40299. PMID: 39605823 -
Eur J Med Res
Long non-coding RNA NORAD serves as a promoter of oncogenesis and inhibits ferroptosis via miR-144-3p-mTOR-ferritinophagy axis in cancer. [Abstract]2025 Aug 4;30(1):704. PMID: 40760677 -
Hum Cell
Hyaluronic acid-modified milk exosomes carrying ZNF516 inhibit ABCC5 and contribute to pemetrexed sensitivity in lung adenocarcinoma. [Abstract]2025 Apr 19;38(3):92. PMID: 40253507 -
Integr Cancer Ther
Chinese Herbal Compound Xiaoliu Pingyi Recipe Inhibits the Growth of Lung Adenocarcinoma by Regulating the Tumor Vascular Microenvironment. [Abstract]2024 Jan-Dec:23:15347354241273962. PMID: 39223822 -
Clin Transl Oncol
Establishment of an acquired lorlatinib-resistant cell line of non-small cell lung cancer and its mediated resistance mechanism. [Abstract]2022 Nov;24(11):2231-2240. PMID: 35852680 -
Odontology
Accumulated cytotoxicity of CDK inhibitor dinaciclib with first-line chemotherapy drugs in salivary adenoid cystic carcinoma cells. [Abstract]2020 Apr;108(2):300-311. PMID: 31529315
Pemetrexed disodium purchased from MedChemExpress. Usage Cited in: Odontology. 2020 Apr;108(2):300-311. [Abstract]
Cell proliferation and viability of ACC-2 cell lines treated with Pemetrexed disodium (0.01-2 μg/mL; 48 h) were measured by the Cell Counting Kit-8 (CCK-8).
Pemetrexed disodium purchased from MedChemExpress. Usage Cited in: Odontology. 2020 Apr;108(2):300-311. [Abstract]
Pemetrexed disodium (0.5 μg/mL; 48 h) caused significant cytotoxicity effects on ACC-2 cells.
Pemetrexed disodium purchased from MedChemExpress. Usage Cited in: Odontology. 2020 Apr;108(2):300-311. [Abstract]
Pemetrexed disodium (0.5 μg/mL; 12 h) increased early stage apoptotic and total apoptotic cells in ACC-2 cells.
Pemetrexed disodium purchased from MedChemExpress. Usage Cited in: Odontology. 2020 Apr;108(2):300-311. [Abstract]
Pemetrexed disodium (0.5 μg/mL; 24 h) decreased RNAP II levels in ACC-2 cells.
-
Pharmacol Res Perspect
Applicability of free drug hypothesis to drugs with good membrane permeability that are not efflux transporter substrates: A microdialysis study in rats. [Abstract]2020 Apr;8(2):e00575. PMID: 32266794 -
Beilstein J Org Chem
Structural diversity in the host-guest complexes of the antifolate pemetrexed with native cyclodextrins: gas phase, solution and solid state studies. [Abstract]2017 Oct 25:13:2252-2263. PMID: 29114329 -
Biol Methods Protoc
Optimizing drug sensitivity assays in patient-derived tumor organoids: a comparison of IC50 estimation methods and experimental parameters. [Abstract]2025 Feb 13;10(1):bpaf012. PMID: 40060949 -
-
-
-
-
-
-
Solvant et solubilité
H2O : 100 mg/mL (212.15 mM; ultrasonic and warming and heat to 60°C)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 50 mg/mL (106.07 mM); Clear solution; Need ultrasonic
Add each solvent one by one: Saline
Solubility: 100 mg/mL (212.15 mM); Clear solution; Need ultrasonic
Protocole
Dose-response curves are generated to determine the concentration required for 50% inhibition of growth (IC50). Pemetrexed is dissolved initially in DMSO at a concentration of 4 mg/mL and further diluted with cell culture medium to the desired concentration. CCRF-CEM leukemia cells in complete medium are added to 24-well Cluster plates at a final concentration of 4.8×104 cells/well in a total volume of 2 mL. Test compounds at various concentrations are added to duplicate wells so that the final volume of DMSO is 0.5%. The plates are incubated for 72 h at 37°C in an atmosphere of 5% CO2 in air. At the end of the incubation, cell numbers are determined on a ZBI Coulter counter. Control wells usually contain 4×105 to 6×105 cells at the end of the incubation. For several studies, IC50s are determined for each compound in the presence of either 300 μM AICA, 5 μM thymidine, 100 μM hypoxanthine, or combination of 5 μM hymidine plus 100 μM hypoxanthine[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice[2]
Female CBA mice and female NOD/SCID mice (NOD.CB17-Prkdcscid) at 6-8 wk of age are used. Premetrexed (100 mg/kg) is given i.p. from days 4-8 (5 consecutive d) to tumor-bearing mice to explore the synergistic effect when combined with anti-CD25 Ab or IgG control. The dose and schedule used for Pemetrexed in the current study is determined based on previous studies in mice.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureté et documentation
-
Fiche technique (277 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Shih C, et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 1997 Mar 15;57(6):1116-23. [Content Brief]
[2]. Anraku M, et al. Synergistic antitumor effects of regulatory T cell blockade combined with pemetrexed in murine malignantmesothelioma. J Immunol. 2010 Jul 15;185(2):956-66. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 2.1215 mL | 10.6074 mL | 21.2148 mL | 53.0369 mL |
| 5 mM | 0.4243 mL | 2.1215 mL | 4.2430 mL | 10.6074 mL | |
| 10 mM | 0.2121 mL | 1.0607 mL | 2.1215 mL | 5.3037 mL | |
| 15 mM | 0.1414 mL | 0.7072 mL | 1.4143 mL | 3.5358 mL | |
| 20 mM | 0.1061 mL | 0.5304 mL | 1.0607 mL | 2.6518 mL | |
| 25 mM | 0.0849 mL | 0.4243 mL | 0.8486 mL | 2.1215 mL | |
| 30 mM | 0.0707 mL | 0.3536 mL | 0.7072 mL | 1.7679 mL | |
| 40 mM | 0.0530 mL | 0.2652 mL | 0.5304 mL | 1.3259 mL | |
| 50 mM | 0.0424 mL | 0.2121 mL | 0.4243 mL | 1.0607 mL | |
| 60 mM | 0.0354 mL | 0.1768 mL | 0.3536 mL | 0.8839 mL | |
| 80 mM | 0.0265 mL | 0.1326 mL | 0.2652 mL | 0.6630 mL | |
| 100 mM | 0.0212 mL | 0.1061 mL | 0.2121 mL | 0.5304 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Powered by Bioz